Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1963 3
1964 2
1966 1
1967 2
1968 1
1969 3
1970 1
1971 3
1972 3
1973 4
1974 4
1975 3
1976 4
1977 8
1978 9
1979 15
1980 10
1981 10
1982 8
1983 9
1984 6
1985 13
1986 14
1987 18
1988 19
1989 16
1990 20
1991 22
1992 27
1993 27
1994 24
1995 25
1996 23
1997 35
1998 26
1999 29
2000 26
2001 24
2002 22
2003 26
2004 20
2005 19
2006 16
2007 28
2008 18
2009 23
2010 25
2011 26
2012 30
2013 28
2014 31
2015 26
2016 26
2017 27
2018 29
2019 38
2020 52
2021 70
2022 72
2023 66
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

1,150 results

Results by year

Filters applied: . Clear all
Page 1
Revisiting Buruli ulcer.
Yotsu RR, Murase C, Sugawara M, Suzuki K, Nakanaga K, Ishii N, Asiedu K. Yotsu RR, et al. Among authors: sugawara m. J Dermatol. 2015 Nov;42(11):1033-41. doi: 10.1111/1346-8138.13049. Epub 2015 Sep 1. J Dermatol. 2015. PMID: 26332541 Review.
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Kohagura K, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Kohagura K, et al. Among authors: sugawara m. Hypertens Res. 2023 Jun;46(6):1417-1422. doi: 10.1038/s41440-023-01198-x. Epub 2023 Feb 7. Hypertens Res. 2023. PMID: 36750608 Clinical Trial.
Conceptual and empirical bridges between micro- and macroevolution.
Rolland J, Henao-Diaz LF, Doebeli M, Germain R, Harmon LJ, Knowles LL, Liow LH, Mank JE, Machac A, Otto SP, Pennell M, Salamin N, Silvestro D, Sugawara M, Uyeda J, Wagner CE, Schluter D. Rolland J, et al. Among authors: sugawara m. Nat Ecol Evol. 2023 Aug;7(8):1181-1193. doi: 10.1038/s41559-023-02116-7. Epub 2023 Jul 10. Nat Ecol Evol. 2023. PMID: 37429904 Review.
Targeting Podoplanin for the Treatment of Osteosarcoma.
Takemoto A, Takagi S, Ukaji T, Gyobu N, Kakino M, Takami M, Kobayashi A, Lebel M, Kawaguchi T, Sugawara M, Tsuji-Takayama K, Ichihara K, Funauchi Y, Ae K, Matsumoto S, Sugiura Y, Takeuchi K, Noda T, Katayama R, Fujita N. Takemoto A, et al. Among authors: sugawara m. Clin Cancer Res. 2022 Jun 13;28(12):2633-2645. doi: 10.1158/1078-0432.CCR-21-4509. Clin Cancer Res. 2022. PMID: 35381070 Free PMC article.
Gefitinib-induced Myositis: A Novel Case Report.
Sakamoto T, Saito Y, Takekuma Y, Kikuchi E, Sugawara M. Sakamoto T, et al. Among authors: sugawara m. Yakugaku Zasshi. 2023;143(7):617-620. doi: 10.1248/yakushi.23-00007. Yakugaku Zasshi. 2023. PMID: 37394456 Free article.
Effect of febuxostat on clinical outcomes in patients with hyperuricemia and cardiovascular disease.
Konishi M, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Konishi M, et al. Among authors: sugawara m. Int J Cardiol. 2022 Feb 15;349:127-133. doi: 10.1016/j.ijcard.2021.11.076. Epub 2021 Dec 3. Int J Cardiol. 2022. PMID: 34864084 Clinical Trial.
1,150 results